Aclaris Therapeutics ACRS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.3%+3.1pp | 73.3%-12.3pp | 85.6%-0.2pp | 85.8%-0.2pp | 86%+0.9pp | |
| Operating margin | -961.9%+14.0pp | -975.9%-2.0pp | -973.9%-101pp | -873.4%-79.8pp | -793.6%-35.4pp | |
| Net margin | -832.6%-3.0pp | -829.6%+70.4pp | -900%-98.0pp | -802%-69.6pp | -732.4%-27.0pp | |
| Returns | ||||||
| Return on equity | -48.4%+1.8pp | -50.2%+63.0pp | -113.2%-11.8pp | -101.4%-10.4pp | -91%-6.6pp | |
| Return on invested capital | -69%+0.8pp | -69.8%+98.4pp | -168.2%-36.4pp | -131.8%-6.9pp | -124.9%-13.4pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 4×+0.7× | 3.4×-0.6× | 3.9×0.0× | 3.9×-1.2× | 5.1×+1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $1.12+32.6% | $0.84-14.1% | $0.98-8.9% | $1.07-8.7% | $1.18-41.5% | |
| Valuation | ||||||
| Market capitalization | $685.75M+337% | $326.12M+58.4% | $205.83M+25.1% | $164.59M-0.5% | $165.47M-37.7% | |
| Price / sales | 82×+73.1× | 41.7×+28.6× | 13.1×+3.3× | 9.8×+0.5× | 9.3×-4.9× | |
| Price / book | 4.8×+3.7× | 3.2×+1.4× | 1.7×+0.5× | 1.2×+0.1× | 1.1×-0.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aclaris Therapeutics's profit margins?
- Aclaris Therapeutics (ACRS) runs a 76.3% gross margin and a -961.9% operating margin, with a -832.6% net margin.
- Where do Aclaris Therapeutics's ratios come from?
- Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
